Biomedical Engineering Letters

, Volume 4, Issue 1, pp 73–79

Parametric response mapping of longitudinal PET scans and their use in detecting changes in Alzheimer’s diseases

Original Article

Abstract

Purpose

The purpose of this study is to determine the effectiveness of an image analysis method called parametric response mapping (PRM) in predicting changes related to progression of Alzheimer’s disease (AD).

Methods

Forty patients were obtained from the ADNI database. Each patient underwent longitudinal 18F Fludeoxyglucose (FDG) positron emission tomography (PET) imaging. The patients were divided into four groups, the NC group (n = 10) with stable normal control (NC) patients, the NC-to-MCI group (n = 10) with converting patients from NC to mild cognitive impairment (MCI), the MCI group (n = 10) with stable MCI patients, and the MCI-to-AD group (n = 10) with converting patients from MCI to AD. The PRM approach was applied to longitudinal PET scans using the following procedures; 1) Longitudinal scans were co-registered, 2) intensities were normalized using the cerebral mask, 3) an expert drew regions of interest (ROIs) for tumor volumes, and 4) voxels were classified into unchanged, increased, and decreased categories.

Results

PRM analysis results were analyzed with linear regression and the slopes of regression lines corresponding to different groups were compared. The PRM analysis was able to distinguish between the NC and NC-to-MCI group with p-value 0.05, while it was not able to distinguish between the MCI and the MCI-to-AD group with p-value 0.54.

Conclusions

An image analysis method, PRM approach, was able to distinguish between stable NC patients and converting patients from NC to MCI.

Keywords

Alzheimer’s disease Positron emission tomography Parametric response mapping Longitudinal analysis Early detection of AD 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi MH. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007; 3(3):186–191.CrossRefGoogle Scholar
  2. [2]
    Abdel-Salam OM. Stem cell therapy for Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2011; 10(4):459–485.CrossRefGoogle Scholar
  3. [3]
    Li Y, Wang Y, Wu G, Shi F, Zhou L, Lin W, Shen D. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer’s disease using dynamic and network features. Neurobiol Aging. 2012; 33(2):427.e 15–30.CrossRefGoogle Scholar
  4. [4]
    Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry. 2002; 159(5):738–745.CrossRefGoogle Scholar
  5. [5]
    Fischl B. FreeSurfer. Neuroimage. 2012; 62(2):774–781.CrossRefGoogle Scholar
  6. [6]
    Kim JS, Singh V, Lee JK, Lerch J, Ad-Dab’bagh Y, MacDonald D, Lee JM, Kim SI, Evans AC. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage. 2005; 27(1):210–221.CrossRefGoogle Scholar
  7. [7]
    Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995; 2:189–210.CrossRefGoogle Scholar
  8. [8]
    Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009; 15(5):572–576.CrossRefGoogle Scholar
  9. [9]
    Hmastra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukheriji SK, Quint DJ, Gerbarski SG, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA. 2005; 102(46):16759–16764.CrossRefGoogle Scholar
  10. [10]
    Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005; 102(15):5524–5529.CrossRefGoogle Scholar
  11. [11]
    Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2012; 8(4):337–342.CrossRefGoogle Scholar
  12. [12]
    Dukart J, Mueller K, Horstmann A, Vogt B, Frisch S, Barthel H, Becker G, Möller HE, Villringer A, Sabri O, Schroeter ML. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage. 2010; 49(2):1490–1495.CrossRefGoogle Scholar
  13. [13]
    Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, Koral K, Frey KA, Wahl RL. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal. 1997; 1(3):195–206.CrossRefGoogle Scholar
  14. [14]
    Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273–289.CrossRefGoogle Scholar
  15. [15]
    Park H, Yang J, Seo J, Lee JM. Dimensionality reduced cortical features and their use in predicting longitudinal changes in Alzheimer’s disease. Neurosci Lett. 2013; 550:17–22.CrossRefGoogle Scholar
  16. [16]
    Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM. Brain regional correspondence between Alzheimer’s Disease histopathology and biomarkers of protein oxidation. J Neurochem. 1995; 65(5):2146–2156.CrossRefGoogle Scholar
  17. [17]
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3):306–319.CrossRefGoogle Scholar
  18. [18]
    Ito M, Seong Hong SJ, Lee JS. Positron emission tomography (PET) detectors with depth-of-interaction (DOI) capability. Biomed Eng Lett. 2011; 1(2):70–81.CrossRefGoogle Scholar
  19. [19]
    Lee D, Park B, Jang C, Park HJ. Decoding brain states using functional magnetic resonance imaging. Biomed Eng Lett. 2011; 1(2):82–88.CrossRefGoogle Scholar
  20. [20]
    Minhas AS, Kim HH, Meng ZJ, Kim YT, Kim HJ, Woo EJ. Three-dimensional MREIT simulator of static bioelectromagnetism and MRI. Biomed Eng Lett. 2011; 1(2):129–136.CrossRefGoogle Scholar
  21. [21]
    Kim HS, Cho MH, Lee YS. Sparse-view CT imaging of trabecular bones: comparison of image reconstruction methods. Biomed Eng Lett. 2011; 1(3):188–193.CrossRefGoogle Scholar
  22. [22]
    Mohapatra S, Patra D, Kumar S, Satpathy S. Lymphocyte image segmentation using functional link neural architecture for acute leukemia detection. Biomed Eng Lett. 2012; 2(2):100–110.CrossRefGoogle Scholar
  23. [23]
    Woo SJ, Kim SJ, Zhoue JA, Kim ET, Seo JM, Park JH, Kim YK, Lee JS, Kim SJ, Chung H. Imaging of activated cortical areas after light and electrical stimulation of the rabbit retina: F-18 FDG PET-guided brain mapping. Biomed Eng Lett. 2012; 2(2):111–117.CrossRefGoogle Scholar
  24. [24]
    Gaidhane VH, Hote YV, Singh V. Nonrigid image registration using efficient similarity measure and levenberg-marquardt optimization. Biomed Eng Lett. 2012; 2(2):118–123.CrossRefGoogle Scholar

Copyright information

© Korean Society of Medical and Biological Engineering and Springer 2014

Authors and Affiliations

  1. 1.School of Electronic and Electrical EngineeringSungkyunkwan UniversitySuwonKorea

Personalised recommendations